Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ruxotemitide - Lytix Biopharma/Verrica Pharmaceuticals

Next Previous
X
Search
Drug Profile

Ruxotemitide - Lytix Biopharma/Verrica Pharmaceuticals

Alternative Names: Cancer-vaccine-Lytix-Biopharma; LTX-315; Oncopore; VP-315; VP-LTX-315

Latest Information Update: 13 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lytix Biopharma
  • Developer Lytix Biopharma; Verrica Pharmaceuticals
  • Class Adjuvants; Amides; Amines; Antineoplastics; Benzyl compounds; Butylamines; Immunotherapies; Indoles; Peptides
  • Mechanism of Action Cell membrane structure modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Basal cell cancer; Malignant melanoma; Soft tissue sarcoma
  • Phase I/II Solid tumours
  • No development reported Carcinoma; Triple negative breast cancer

Most Recent Events

  • 01 Nov 2024 Phase-II clinical trials in Malignant melanoma (Combination therapy, Neoadjuvant therapy, Late-stage disease) in Norway (Intratumoural) (NCT06651151)
  • 29 Aug 2024 Lytix Biopharma plans the phase II NeoLIPA (ATLAS-IT-06) trial for Malignant melanoma (Neoadjuvant therapy, Combination therapy) in Norway (Intratumoural, Injection), in third quater of 2024 (Lytix Biopharma pipeline, October 2023)
  • 14 Aug 2024 Verrica Pharmaceuticals plans an End-of-Phase II meeting with US FDA to determine next steps for the development of Ruxotemitide for Basal cell cancer in the first half of 2025

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top